STUDY OF INTERACTION OF AQUEOUS EXTRACT OF PLEUROTUS PULMONARIUS (FR.) QUEL-CHAMP WITH ROSIGLITAZONE IN ALLOXAN INDUCED DIABETIC MICE

Sachin L. Badole, Subhash L. Bodhankar* and Prasad A. Thakurdesai

Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune 411 038, India.

Summary

Mushrooms are low calorie food with very little fat, no starch and very low sugars, and so are the “delight of the diabetics”. Recently, we have reported significant hypoglycemic activity of aqueous extract of Pleurotus pulmonarius (Family: Lentinaceae) (PP-aqu) on serum glucose levels and oral glucose tolerance test (OGTT) in alloxan induced diabetic mice at and more than 500 mg/kg, p.o. Herbal agents when given in combination with prescription medication may favorably alter pharmacodynamic activity of prescription medications. Hence, we have evaluated the antihyperglycemic effect of combination of PP-aqu (500 mg/kg, p.o.) with rosiglitazone (6 mg/kg, p.o.) on serum glucose levels and oral glucose tolerance test (OGTT) in alloxan induced diabetic mice. Our results from acute and sub-acute studies suggest that combination treatment of PP-aqu with rosiglitazone has synergistic antihyperglycemic effect than either drug alone. Concurrent drug regimen of PP-aqu and rosiglitazone may be considered for effective diabetes control.

Keywords: Pleurotus pulmonarius (Fr.) Quel-Champ, Rosiglitazone; Alloxan induced diabetic mice, Oral glucose tolerance test (OGTT)

*Corresponding author: Dr. Subhash L. Bodhankar, Professor and Head, Department of Pharmacology, Bharati Vidyapeeth Deemed University, Erandwane, Paud Road, Pune-38, Tel: +91-20-25437237 Ext-29, Fax: +91-20-25439383, E-mail: sbodh@yahoo.com
Introduction

Mushrooms are a group of fleshy macroscopic fungi, and have been valued throughout the world as both food and medicine for thousands of years (1, 2). Mushrooms are highly nutritive as they contain good quality proteins, vitamins and minerals (3, 4). Mushrooms are low calorie food with very little fat, no starch and very low sugars, and so are the “delight of the diabetics” (5). In adequate quantities they can serve as medicinal foods for diabetes. Earlier studies have reported insulin release and insulin like activity of some mushroom species like *Agaricus campestris* (6-8).

Among many varieties of mushrooms species, *Pleurotus pulmonarius* (Family: Lentinaceae) are characterized by a white spore print and commonly known as “oyster mushroom” (9). Recently, we have reported significant hypoglycemic activity of *Pleurotus pulmonarius* on serum glucose levels and oral glucose tolerance test (OGTT) in alloxan induced diabetic mice at dose levels of 500 mg/kg, p.o. and higher (10).

When used as directed and under the supervision of knowledgeable individuals most herbal remedies are safe. Herbal agents when given in combination with prescription medication may favorably alter pharmacokinetic (11) as well as pharmacodynamics (12-14) of prescription medications. However, the potential for adverse effects or intoxications certainly exists (15). To date, evidence relating to the herb-drug interaction in case of antidiabetic medicines is lacking and the understanding of the involved mechanisms is far from complete. Hence, we have evaluated the antihyperglycemic effect of aqueous extract of *Pleurotus pulmonarius* (PP-aqu) and its interaction with rosiglitazone on serum glucose levels and oral glucose tolerance test (OGTT) in alloxan induced diabetic mice.

Material and Methods

Drugs and chemicals

*Pleurotus pulmonarius* (Fr.) Quel.-Champ (Lentinaceae) was provided to us as a gift sample from Bajaj Orchard, Pvt. Ltd., Mumbai, India. It was authenticated by Dr. A. M. Mujumdar, Department of Botany, at Agharkar Research Institute, Pune and voucher specimen was deposited at that Institute. Rosiglitazone (Rosi) (USV. Pharma. Ltd., Mumbai, India), alloxan monohydrate (Spectrochem, India), glucose estimation kit (Accurex Biomedical Pvt. Ltd., India) and d-glucose (S.D. Fine-Chem. Ltd, India) were purchased from respective companies.

Experimental animals

Swiss albino mice (25-30 g) were purchased from National Toxicology Centre, Pune, India. They were maintained at a temperature of 25 ± 1 °C and relative humidity of 45 to 55 % under 12-h light:12-h dark cycle. The animals had free access to food pellets (Chakan Oil Mills, Pune, India) and water ad libitum. The experimental protocol was
approved by the Institutional Animal Ethics Committee (IAEC) of Poona College of Pharmacy, Pune, India.

**Preparation of aqueous extract of Pleurotus pulmonarius (PP-aqu)**

Weighed quantity powder of air-dried *Pleurotus pulmonarius* was added to distilled water (1:15), boiled for 20 min on water bath, cooled to room temperature and filtered. The filtrate was dried on tray dryer at 70 °C. (Yield - 24% w/w). The dry extract powder was dissolved in distilled water to prepare the drug solution of concentration of 100 mg/ml and used for pharmacological studies.

**Induction of experimental diabetes**

Diabetes was induced in mice by a single intravenous injection of aqueous alloxan monohydrate (70 mg/kg, i.v.) by the method described by Rao et al (16). After 48 hours, the animals showing serum glucose level above 200 mg/dl (diabetic) were selected for the study. All the animals were allowed free access to tap water and pellet diet.

**Collection of blood and determination of serum glucose**

Blood samples from the control and experimental mice were collected by orbital sinus puncture using heparinised capillary glass tubes. The blood samples so collected were analyzed for glucose levels by glucose oxidase peroxidase (GOD/POD) method as described earlier (17) and serum glucose levels were expressed as mg/dl.

**Alloxan induced diabetic mice model (10)**

The diabetic mice were divided into six groups of six animals each. The mice were administered orally with either vehicle (distilled water, 10 ml/kg), PP-aqu (500 mg/kg), Rosi (6 mg/kg), and the combination of PP-aqu (500 mg/kg) with Rosi (6 mg/kg). Acute study involved estimation of serum glucose at 0, 2, 4, 6 and 24 h after drug administration. Sub acute study involved repeated administration of drug for 14 days at prefixed time and serum glucose level was estimated on 7th and 14th day. Mean change in serum glucose level and standard error of Mean (SEM) were calculated. The mice were weighed daily during the study period of 14 days and their body weights were noted. From this data, mean change in body weight and SD were calculated. The mortality of mice was also noted during the study period and percentage mortality was calculated.

**Oral glucose tolerance test (OGTT) in alloxan treated diabetic mice**

Diabetic and non-fasted mice were divided into five groups of six animals each. They were administered orally with either vehicle (distilled water, 10 ml/kg), PP-aqu (500 mg/kg), Rosi (6 mg/kg), and the combination of PP-aqu (500 mg/kg) with Rosi (6 mg/kg). The mice of all the groups were loaded with d-glucose (2.5 gm/kg) solution after half an hour of drug administration. Serum glucose was estimated prior to drug
administration and at 30, 60 and 120 minutes after glucose loading and mean serum glucose levels were calculated.

**Statistical analysis**

The results are expressed as mean ± SEM. Comparison between the groups was made by Two-way analysis of variance (ANOVA) followed by *post hoc* Dunnett’s test.

**Results**

PP-aqu (500 mg/kg, p.o.) and Rosi (6 mg/kg, p.o.) after acute administration in alloxan induced diabetic mice showed significant (p < 0.01) decrease in fasting serum glucose level as compared with their corresponding pre-treatment readings. However, as revealed by Figure 1, the effect of PP-aqu and combination treatment was strong (P < 0.001) even at 24 hrs. where anti-hyperglycemic effect of rosiglitazone was started diminishing (P < 0.05). After sub-acute administration, PP-aqu, rosi and combination treatment caused strong anti-hyperglycemic effect (P < 0.001) as compared with their pre-treatment glucose levels (Figure 2).

![Figure 1: Effect of acute pretreatment of aqueous extract of *P. pulmonarius* (PP-aqu) and rosiglitazone on serum glucose level in alloxan induced diabetes in mice. n = 6, Data was analyzed by Two-way ANOVA followed by *post hoc* Dunnett's test. * P < 0.05), ** P < 0.01 and *** P < 0.001 as compared to pre-treatment readings of respective treatment group. All other values are non significant as compared with pre-treatment readings of respective treatment group.](image-url)
After alloxan treatment, mice lost their body weight significantly as revealed by vehicle control group (Figure 3). This loss of body weight was shown to be prevented by PP-aqu, or rosi treatment till day-14 but not on day-21 and day-28 (Figure 3). On the other hand, combination (PP-aqu + rosi) treatment prevented body weight loss of mice on day-21. On day-28, all treatment showed loss of body weight but combination group showed mild loss (P < 0.05) than per se treatment of either PP-aqu or rosi (P < 0.001).

Oral glucose load (2.5 g /kg) significantly increased serum glucose level (P < 0.001) as shown in Figure 4. After treatment with PP-aqu, rosi or their combination, serum glucose level was reduced significantly (P < 0.001). This decrease in serum glucose levels at 60 and 120 min was more after combination treatment (PP-aqu + rosiglitazone) than any of treatment alone (Figure 4).
Figure 3: Effect of sub-acute pretreatment of aqueous extract of *P. pulmonarius* (PP-aqu) and rosiglitazone on body weights of alloxan induced diabetes in mice. Data was analyzed by Two-way ANOVA followed by post hoc Dunnett's test. ns – non significant * P < 0.05, ** P < 0.01 and *** P < 0.001 as compared to pre-treatment readings of respective treatment group.

Figure 4: Effect of acute pretreatment of aqueous extract of *P. pulmonarius* (PP-aqu) and rosiglitazone on serum glucose level in oral glucose tolerance test (OGTT) in mice. Data was analyzed by Two-way ANOVA followed by post hoc Dunnett's test. ns – non significant # P < 0.05 and ### P < 0.001 as compared with reading of normal mice. * P < 0.05 and *** P < .001 as compared to pre-treatment readings (at 0 min) of respective treatment group.
Discussion

The results obtained are in support with our previous study on anti-hyperglycemic effect of PP-aqu (10). With increasing use of herbal medicinal products, adverse herb-drug interactions may be of significant public health consequence (18, 19). Moreover, nearly all herbal remedies contain multiple, biologically active constituents, and so interaction with conventional drugs is a important concern for medicinal use of herbs (20-22). In fact, the likelihood of herb-drug interactions is reported to be theoretically higher than drug-drug interactions (15). On the other hand, combination of herbal drugs (or isolated phytochemicals) are found to be beneficial in certain diseases (12) when given along with conventional drugs. Our results further suggested the use of PP-aqu as adjunct treatment with rosi for the effective control of type-2 diabetes.

Preliminary phytochemical analysis of the *P. pulmonarius* showed presence of proteins, minerals, vitamins and carbohydrates and are in line with earlier reports by Food and Agriculture Organization (23). Although, the active principle(s) in mushroom responsible for these effects remain to be elucidated but guanide (a phytochemical) has been detected in edible mushroom and has known hypoglycaemic effects (24). The ability of lectins isolated from other varieties of mushrooms (*A. campestris, A. bispourus*) to enhance insulin release by isolated rat Islets of Langerhans has been documented by Ewart el al (6, 25)

The glitazones are known to enhance tissue sensitivity to insulin rather than stimulates insulin secretion. Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production by acting primarily on peroxisome proliferator activated receptor gamma (PPAR-γ) (26) and increases glucose clearance in patients with type 2 diabetes mellitus (27). The combination of *P. pulmonarius* and rosiglitazone may resulted in increasing the sensitivity of insulin and thus reduction in glucose levels are observed.

Conclusions

It is thus apparent that *P. pulmonarius* and rosiglitazone possesses significant synergistic antihyperglycemic activity. Addition of *P. pulmonarius* in diabetes regimen might improve the efficiency of rosiglitazone and appears to be a possible combination drug therapy for the treatment of diabetes mellitus.

Acknowledgements

The author would like to thank Dr. S. S. Kadam, Principal, and Dr. K.R. Mahadik Vice-Principal, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune for providing necessary facilities and Bajaj Orchard, Mumbai for gift sample of *P. Pulmonarius*. 
References


